Letter: thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease

E-ISSN： 1365-2036|41|5|494-495

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.5, 2015-03, pp. : 494-495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease

By Roberts Rebecca L Gearry Richard B Kennedy Martin A Barclay Murray L

Personalized Medicine, Vol. 5, Iss. 3, 2008-05 ,pp. : 233-248

Future Medicine

Access to resources Recommend Favorite

Factors associated with thiopurine non‐adherence in patients with inflammatory bowel disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1097-1108

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: cytomegalovirus infection in inflammatory bowel disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 1, 2015-07 ,pp. : 127-129

John Wiley & Sons Inc

Access to resources Recommend Favorite

Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1025-1037

John Wiley & Sons Inc

Access to resources Recommend Favorite

Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 2, 2018-02 ,pp. : 259-270

John Wiley & Sons Inc

Access to resources Recommend Favorite